Goodwin Procter attorneys recently advised Royalty Pharma in a $3.3 billion acquisition of the Cystic Fibrosis Foundation’s royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments, the largest pharmaceutical royalty purchase ever completed. Funds will be used to expand cystic fibrosis research, care and service programs.
Royalty Pharma is a global leader in life sciences financing, focused on providing liquidity to inventors, research laboratories and life-science companies. Founded in 1996, Royalty Pharma owns royalty interests in forty approved and marketed biopharmaceutical products, with total assets over $12 billion.
Cystic Fibrosis Foundation is a nonprofit, donor-supported organization, leading the search for a cure for Cystic Fibrosis. The foundation funds research and works to provide access to quality, specialized care and effective treatments for people with CF.
The Goodwin deal team was led by associate Bethany Withers.
For more information about this transaction, please read the press release. The deal also received significant media attention, with coverage in The New York Times, Reuters, Bloomberg and Xconomy.